Nautilus Biotechnology price target lowered to $2.50 from $4 at Guggenheim

Guggenheim lowered the firm’s price target on Nautilus Biotechnology (NAUT) to $2.50 from $4 and keeps a Buy rating on the shares. A key area of focus was on the commercial launch timeline, which was pushed out a year to the end of 2026 from a prior view of the end of 2025, the analyst tells investors.